Trial Search Results
Acute Treatment of Bipolar II Depression
This study will compare the medications lithium and lamotrigine (Lamictal®) in treating depression in individuals with bipolar II disorder.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Stanford University
Collaborator: National Institute of Mental Health (NIMH)
Stanford Investigator(s):
Intervention(s):
- Drug: Lithium
- Drug: Lamotrigine
Phase:
Phase 3
Eligibility
Inclusion Criteria:
- Current diagnosis of bipolar II disorder
Exclusion Criteria:
- Use of lithium or lamotrigine
- Intolerance to lithium or lamotrigine
- Substance abuse or dependence within the last month
- Suicidal thoughts
- Unstable medical conditions
- Pregnancy or breast-feeding
- Stable on current medications
- Use of fluoxetine (Prozac) within 2 weeks of study
- Require an antipsychotic medication
- Do not speak or read English
Ages Eligible for Study
18 Years - 55 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting